Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crisaborole - Pfizer

Next Previous
Drug Profile

Crisaborole - Pfizer

Alternative Names: AN-2728; Crisaborole ointment; Eucrisa; PF-06930164; PF-06940799; STAQUIS

Latest Information Update: 20 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anacor Pharmaceuticals; Sheffield Teaching Hospitals NHS Foundation Trust; University of Sheffield
  • Developer Anacor Pharmaceuticals; Duke University; Pfizer Canada; Sheffield Teaching Hospitals NHS Foundation Trust; University of Sheffield
  • Class Anti-inflammatories; Antipsoriatics; Benzonitrile; Heterocyclic bicyclo compounds; Nonsteroidal anti-inflammatories; Organic boron compounds; Phenyl ethers; Skin disorder therapies; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Phase II Circumscribed scleroderma; Vitiligo
  • Suspended Psoriasis
  • Discontinued Dermatitis

Most Recent Events

  • 30 Apr 2024 University of Colorado in collaboration with Pfizer completes a Phase-II clinical trials in Vitiligo in USA (Topical) (NCT05298033)
  • 10 May 2023 Efficacy and safety data from a phase II trial in Dermatitis presented at the American Academy of Dermatology annual Meeting 2023
  • 23 Sep 2022 Phase-II clinical trials in Vitiligo in USA (Topical) (NCT05298033)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top